Long-Term Outcome of Subjects With Elevated PSA in Healthy Taiwanese Men

To determine the long-term survival outcome of subjects who had various PSA levels at screening

Completed

Looking for future studies?

Key information

Conditions

Prostate Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

41 year and older

Sex eligibility

Male

Study type

Observational

Primary location

National Taiwan University Hospital

Taipei, 100, Taiwan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Health men who received PSA screening at NTUH and CGMH

Exclusion criteria

Prior history of prostate cancer

Treatment and study plan

Primary outcomes

Diagnosis of prostate cancer

Time frame: 20 years (average)

Secondary outcomes

Cancer-specific death

Time frame: 20 years (average)
Overall survival

Time frame: 20 years (average)

Sponsors and collaborators

Lead sponsor

National Taiwan University Hospital

Other

Registry information

Important dates

Study start: 2012
Primary completion: 2012
First posted: Mar 14, 2014
Registry last updated: Mar 14, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed